SCHEMBL365374

SCHEMBL365374

COc1cc(Cl)cc2cccnc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.50
PDGFRB P09619 1/20 0.50
PDGFRA P16234 1/20 0.50
G6PD P11413 1/20 0.49
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
LMNA P02545 3/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPSR1 Q6W5P4 2/20 0.47
KDM4E B2RXH2 2/20 0.47
HPGD P15428 2/20 0.47
MAPT P10636 1/20 0.47
HTT P42858 1/20 0.47
CCR1 P32246 2/20 0.46
CCR8 P51685 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ALDH1A1 P00352 3/20 0.45
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12996132 0.83 KDM4E (0.52) MEN1KMT2ALMNANPC1RAB9A
SCHEMBL25248278 0.81 PDGFRB (0.51) DYRK1APDGFRBPDGFRAG6PDMEN1
SCHEMBL13301167 0.81 PSMD14 (0.59) DYRK1APDGFRBPDGFRAMEN1KMT2A
SCHEMBL1556194 0.81 CYP1A2 (0.52) DYRK1APDGFRBPDGFRAMEN1KMT2A
SCHEMBL27292852 0.79 HSP90AA1 (0.50) DYRK1APDGFRBPDGFRAMEN1KMT2A
SCHEMBL2943859 0.79 DYRK1A (0.50) DYRK1APDGFRBPDGFRAG6PDMEN1
SCHEMBL3344053 0.79 NQO2 (0.53) DYRK1APDGFRBPDGFRAG6PDMEN1
SCHEMBL30674020 0.79 NQO2 (0.53) DYRK1APDGFRBPDGFRAG6PDMEN1
SCHEMBL27976000 0.78 DYRK1A (0.46) DYRK1APDGFRBPDGFRAG6PDMEN1
SCHEMBL10877348 0.78 LMNA (0.48) MEN1KMT2ALMNASMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4183786-A1 DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES Felicitex Therapeutics, Inc. (US) 2023-05-24 EP disclosed
EP-3558321-B1 DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES FELICITEX THERAPEUTICS INC (US) 2023-02-01 EP disclosed
US-10577365-B2 Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases FELICITEX THERAPEUTICS, INC. (US) 2020-03-03 US disclosed
EP-3558321-A1 DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES Felicitex Therapeutics, Inc. (US) 2019-10-30 EP disclosed
WO-2018119039-A1 DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES FELICITEX THERAPEUTICS, INC. (US) 2018-06-28 WO disclosed
US-20180179199-A1 DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES FELICITEX THERAPEUTICS, INC. (US) 2018-06-28 US disclosed
EP-2593432-B1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS PFIZER LTD (GB) 2014-10-22 EP disclosed
EP-2593432-B1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS PFIZER LTD (GB) 2014-10-22 EP disclosed
US-8592629-B2 Sulfonamide derivatives as Nav 1.7 inhibitors PFIZER LIMITED (GB) 2013-11-26 US disclosed
EP-2593432-A1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS Pfizer Limited (GB) 2013-05-22 EP disclosed
WO-2012007861-A1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-01-19 WO disclosed
WO-2012007861-A1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-01-19 WO disclosed
US-20120010183-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed
US-20120010183-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed
US-20120010183-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010183-A1 Chemical Compounds SCN1A, SCN1B, SCN7A DYRK1A 2935/4885PDGFRB 4055/4885PDGFRA 3161/4885
US-10577365-B2 Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885PDGFRB 1636/4885PDGFRA 1840/4885
US-20180179199-A1 DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885PDGFRB 1636/4885PDGFRA 1840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.